{"result": "(\"entity\"<|>CEFALAE<|>EVENT<|>Cefalea refers to headaches, which are one of the mild symptoms associated with hyponatremia.)\n##\n(\"entity\"<|>DEFICIT DE ATENCIÓN<|>EVENT<|>Deficit de atención refers to attention deficits, which can occur as a mild symptom of hyponatremia.)\n##\n(\"entity\"<|>ALT. MEMORIA<|>EVENT<|>Alteraciones de memoria refers to memory disturbances that can be symptoms of hyponatremia.)\n##\n(\"entity\"<|>MARCHA INESTABLE<|>EVENT<|>Marcha inestable refers to unstable gait, which can be a symptom of hyponatremia.)\n##\n(\"entity\"<|>ALT. COGNITIVA<|>EVENT<|>Alteraciones cognitivas refer to cognitive disturbances that can arise in patients with hyponatremia.)\n##\n(\"entity\"<|>NA SÉRICA<|>EVENT<|>Na sérica refers to serum sodium levels, which are critical in diagnosing and managing hyponatremia.)\n##\n(\"entity\"<|>NATREMIA<|>EVENT<|>Natremia refers to the concentration of sodium in the blood, which is a key factor in the condition of hyponatremia.)\n##\n(\"entity\"<|>SÍNDROME NEFRÓTICO<|>EVENT<|>Síndrome nefrótico is a kidney disorder that can lead to hyponatremia due to fluid retention and protein loss.)\n##\n(\"entity\"<|>INSUFICIENCIA RENAL CRÓNICA<|>EVENT<|>Insuficiencia renal crónica refers to chronic kidney failure, which can contribute to the development of hyponatremia.)\n##\n(\"entity\"<|>INSUFICIENCIA CARDÍACA<|>EVENT<|>Insuficiencia cardíaca refers to heart failure, a condition that can lead to fluid overload and hyponatremia.)\n##\n(\"entity\"<|>CIRROSIS<|>EVENT<|>Cirrhosis is a liver disease that can cause fluid retention and is associated with hyponatremia.)\n##\n(\"entity\"<|>HIPOALDOSTERONISMO AISLADO<|>EVENT<|>Hipoaldosteronismo aislado refers to isolated hypoaldosteronism, a condition that can lead to hyponatremia.)\n##\n(\"entity\"<|>DIURÉTICOS<|>EVENT<|>Diuréticos are medications that can cause hyponatremia as a side effect, particularly thiazide diuretics.)\n##\n(\"entity\"<|>SÍNDROME DE SECRECIÓN INAPROPIADA DE ADH<|>EVENT<|>Síndrome de secreción inapropiada de ADH (SIADH) is a condition that can lead to hyponatremia due to excess ADH secretion.)\n##\n(\"entity\"<|>NATREMIA HIPOVOLÉMICA<|>EVENT<|>Natremia hipovolémica refers to low sodium levels associated with low blood volume, a type of hyponatremia.)\n##\n(\"entity\"<|>NATREMIA EUVOLÉMICA<|>EVENT<|>Natremia euvolémica refers to normal blood volume with low sodium levels, another type of hyponatremia.)\n##\n(\"entity\"<|>NATREMIA HIPERVOLÉMICA<|>EVENT<|>Natremia hipervolémica refers to high blood volume with low sodium levels, a third type of hyponatremia.)\n##\n(\"entity\"<|>TRATAMIENTO DE LA HIPONATREMIA<|>EVENT<|>Tratamiento de la hiponatremia refers to the management and treatment protocols for addressing hyponatremia.)\n##\n(\"entity\"<|>PATOLOGÍAS ASOCIADAS<|>EVENT<|>Patologías asociadas refers to conditions that are related to or can cause hyponatremia.)\n##\n(\"entity\"<|>MANEJO DE LA HIPONATREMIA<|>EVENT<|>Manejo de la hiponatremia refers to the strategies and protocols for managing patients with hyponatremia.)\n##\n(\"entity\"<|>NATREMIA INICIAL<|>EVENT<|>Natremia inicial refers to the initial sodium level measured in patients, crucial for treatment decisions.)\n##\n(\"entity\"<|>SUERO GLUCOSADO<|>EVENT<|>Suero glucosado is a type of intravenous fluid that may be used in the treatment of hyponatremia.)\n##\n(\"entity\"<|>DESMOPRESINA<|>EVENT<|>Desmopresina is a medication that may be used in the management of certain types of hyponatremia.)\n##\n(\"entity\"<|>PAUTA CORRECTORA<|>EVENT<|>Pauta correctora refers to the corrective protocol used to manage sodium levels in patients with hyponatremia.)\n##\n(\"entity\"<|>SUSPENSIÓN DE NUTRICIÓN ARTIFICIAL<|>EVENT<|>Suspensión de nutrición artificial refers to the temporary cessation of artificial nutrition during treatment for hyponatremia.)\n##\n(\"entity\"<|>ANÁLISIS DE NATREMIA<|>EVENT<|>Análisis de natremia refers to the testing of sodium levels in the blood, essential for managing hyponatremia.)\n##\n(\"entity\"<|>TRATAMIENTO DE LA HIPONATREMIA NO GRAVE<|>EVENT<|>Tratamiento de la hiponatremia no grave refers to the management strategies for mild cases of hyponatremia.)\n##\n(\"entity\"<|>EMPEORAMIENTO DE LA HIPONATREMIA<|>EVENT<|>Empeoramiento de la hiponatremia refers to the worsening of sodium levels in patients, which treatment aims to prevent.)\n##\n(\"entity\"<|>EUNATREMIA<|>EVENT<|>Eunatremia refers to normal sodium levels in the blood, which is the goal of treatment for hyponatremia.)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: o cirrosis avanzada). De forma que, en pacientes con riesgo elevado de SDO, las últimas guías recomiendan un incremento máximo de natremia en las primeras 24 horas y a diario, de\n\n| LEVES | MODERADOS | SEVEROS |\n|-------|------------|---------|\n| · Cefalea<br>· Déficit de atención<br>· Alt. memoria<br>· Marcha inestable<br>· Alt. cognitiva | · Náuseas<br>· Vómitos<br>· Desorientación<br>· Somnolencia<br>· Confusión | · Estupor<br>· Coma<br>· Convulsiones<br>· Distrés respiratorio |\n\nEl grado de severidad sube si: · Natremia sérica (NaS) < 120 mmol/l\n                               · Descenso > 10 mmol/l de NaS en 24-48 h\n                               · Hipoxia\n                               · Hemorragia o tumor intracraneal\n                               · Mujeres en edad fértil\n                               · Niños\n\nFigura 3. Clasificación de la clínica neurológica en pacientes con hiponatremia.\nAdaptada de Runkle I et al. Reviews in Clinical Gerontology, 2015.\n\nTabla 4. Diagnóstico diferencial de la causa de hiponatremia en pacientes con nutrición artificial.\n\n| Tipo de hiponatremia | NaU > 20 mmol/l | NaU < 20 mmol/l |\n|----------------------|-----------------|------------------|\n| Hiponatremia hipovolémica | · Diuréticos (tiazidas)<br>· Hipoaldosteronismo aislado<br>· ISP 1.ª | · Pérdidas digestivas (diarrea, vómitos, fístulas, obstrucción intestinal, etc.)<br>· Quemaduras |\n| Hiponatremia euvolémica | · Elevación fisiológica de la ADH (dolor, náusea, estrés post-cirugía)<br>· ISP 2.ª<br>· SIADH | · Bajo aporte de sodio/soluto (administración de fluidos hipotónicos) |\n| Hiponatremia hipervolémica | · Insuficiencia renal crónica/aguda | · Insuficiencia cardíaca<br>· Cirrosis con ascitis<br>· Síndrome nefrótico |\n\nADH: hormona antidiurética; ISP: insuficiencia suprarrenal; NaU: sodio urinario; SIADH: síndrome de secreción inapropiada de ADH.\n---\nBLOQUE: SOPORTE NUTRICIONAL AVANZADO\n\n8 mmol/l. En los pacientes con riesgo bajo de SDO la subida máxima en las primeras 24 horas y a diario, no debe sobrepasar los 10-12 mmol/l, y a las 48 horas los 18 mmol/l⁴⁵. Si a las 24-48 horas postratamiento, se superan los límites previamente citados, se administrará la pauta correctora para inducir un redescenso de la natremia. Esta pauta consta de la administración de suero glucosado (3 ml/kg/h) y desmopresina intravenosa (2-4 μg cada 8 horas). Tras su inicio, se analizará la natremia cada 2 horas y se suspenderá cuando se logre el descenso de natremia buscado (natremia inicial + 6-8 mmol/l)⁴⁵.\n\nDurante la administración de la SSH quizás sea prudente suspender transitoriamente la nutrición artificial. Sobre todo en el caso de la NP, con la finalidad de evitar interferencias con el aporte de volumen e iones de la misma.\n\nEs importante no iniciar ninguna terapia susceptible de elevar aún más la natremia (sueros isotónicos en hipovolémicos, furosemida, tolvaptan, etc.) en las primeras 24 horas postretirada de la SSH⁶⁵, salvo en los pacientes con hiponatremia hipervolémica, en los que se deberá administrar furosemida durante y tras la retirada de la SSH. Pasado este tiempo se iniciará el manejo de la hiponatremia no grave, como se detalla a continuación.\n\n## 5.2. Manejo de la hiponatremia no grave en pacientes con nutrición artificial\n\nEn los pacientes sin clínica neurológica grave (natremia > 120 mmol/l habitualmente), el tratamiento debe ajustarse al tipo de hiponatremia (hipo; hiper y euvolémica) y a su etiología; respetando también los límites de incremento máximo de natremia, previamente citados³⁹, ⁴⁵. El objetivo principal de este tratamiento es alcanzar y mantener la eunatremia; si no es posible, evitar al menos el empeoramiento de la hiponatremia y el desarrollo de una hiponatremia grave.\n\n### 5.2.1. Tratamiento de la hiponatrem\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>RUNKLE I<|>PERSON<|>Runkle I is an author of a study published in Reviews in Clinical Gerontology, 2015, discussing clinical aspects of hyponatremia.)\n##\n(\"entity\"<|>REVIEWS IN CLINICAL GERONTOLOGY<|>ORGANIZATION<|>Reviews in Clinical Gerontology is a publication that features studies and reviews related to clinical gerontology, including topics like hyponatremia.)\n##\n(\"entity\"<|>HIPONATREMIA<|>EVENT<|>Hyponatremia is a medical condition characterized by low sodium levels in the blood, which can lead to various neurological symptoms and requires careful management.)\n##\n(\"entity\"<|>NUTRICIÓN ARTIFICIAL<|>EVENT<|>Artificial nutrition refers to the provision of nutrients through means other than oral intake, often used in patients who cannot eat normally.)\n##\n(\"entity\"<|>ADH<|>ORGANIZATION<|>ADH, or antidiuretic hormone, is a hormone that helps regulate water balance in the body and is relevant in the context of hyponatremia.)\n##\n(\"entity\"<|>FURSEMIDE<|>ORGANIZATION<|>Furosemide is a diuretic medication used to treat fluid retention and high blood pressure, which can be relevant in managing hyponatremia.)\n##\n(\"relationship\"<|>RUNKLE I<|>REVIEWS IN CLINICAL GERONTOLOGY<|>Runkle I authored a study published in Reviews in Clinical Gerontology discussing hyponatremia<|>8)\n##\n(\"relationship\"<|>HIPONATREMIA<|>NUTRICIÓN ARTIFICIAL<|>Hyponatremia management may involve adjustments to artificial nutrition protocols<|>6)\n##\n(\"relationship\"<|>ADH<|>HIPONATREMIA<|>ADH plays a significant role in the regulation of sodium levels and is involved in the pathophysiology of hyponatremia<|>7)\n##\n(\"relationship\"<|>FURSEMIDE<|>HIPONATREMIA<|>Furosemide is used in the treatment of hyponatremia, particularly in cases of hypervolemic hyponatremia<|>7)\n<|COMPLETE|>"}]}